View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Bruno Cavalier
  • Bruno Cavalier
Bruno Cavalier
  • Bruno Cavalier
Amira Manai
  • Amira Manai

HighCo : Record 2023 results - Caution on 2024 due to risks associated...

>Adjusted earnings on ordinary activities of € 16.4m, i.e. an operating margin of 22.1% (+150bp) - Yesterday evening, HighCo reported record earnings for 2023. Despite a gross margin (already published) down 2.7% to € 74.4m, adjusted earnings on ordinary activities came in at € 16.4m, revealing a 150bp improvement to the operating margin to 22.1%, in line with the guidance announced in January and with our forecast (22.1%). This operational performance stems from eff...

Amira Manai
  • Amira Manai

HighCo : Des résultats records en 2023 – Prudence sur 2024 en raison d...

>RAO à 16.4 M€ soit une MOP de 22.1% (+150 pb) - Au titre de son exercice 2023, HighCo a publié hier soir des résultats annuels records. En dépit d’une MB (déjà publiée) en décroissance de 2.7% à 74.4 M€, le RAO s’établit à 16.4 M€, traduisant une MOP en forte croissance de 150 pb à 22.1%, en ligne avec la guidance annoncée en janvier et notre attente (22.1%). Cette performance opérationnelle découle d’une gestion efficace des coûts. Le ROC progresse de 8% à 15.6 M€ a...

Matthias Desmarais
  • Matthias Desmarais
Matthias Desmarais
  • Matthias Desmarais
Andreas Riemann ... (+3)
  • Andreas Riemann
  • Jean Danjou
  • Usama Tariq

ODDO BHF Small & MIDCAP MORNING NEWS - 03/28/2024

With the exception of the US, construction markets should continue to shrink in 2024 (-2% in Europe) before rebounding on the back of lower interest rates. Against this backdrop, groups will be differentiated mainly on the basis of their resilience (geographical and price/cost mix), capital allocation (and special situations) and valuation. In this context, we are upgrading our recommendations on KONE (modernisation as an alternative source of growth to China) and Holcim (a substantia...

Emmanuel Matot
  • Emmanuel Matot

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 28/03/2024

Hormis les Etats-Unis, les marchés de la construction devraient continuer à reculer en 2024 (-2% en Europe) avant de rebondir à la faveur d’une baisse des taux. Dans ce contexte, la différenciation entre les groupes se fera essentiellement sur leur capacité de résistance (mix géographique et prix/ coûts), l’allocation du capital (et situations spéciales) et leur valorisation. Face à cet environnement, nous relevons nos recommandations sur KONE (la modernisation comme relais de la Chin...

Emmanuel Matot
  • Emmanuel Matot

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/28/2024

With the exception of the US, construction markets should continue to shrink in 2024 (-2% in Europe) before rebounding on the back of lower interest rates. Against this backdrop, groups will be differentiated mainly on the basis of their resilience (geographical and price/cost mix), capital allocation (and special situations) and valuation. In this context, we are upgrading our recommendations on KONE (modernisation as an alternative source of growth to China) and Holcim (a substantia...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Transgene : A strengthening of its cash position which should reassure

>Clear confidence in its historic shareholder - Last night, TNG published its annual results, which should reassure the markets following the signature of a new credit line with Institut Mérieux. Operating revenues were logically down at € 7.9m versus € 10.3m, mainly due to the termination of its agreement with AstraZeneca. On the other hand, operating expenses were well under control overall, despite the clinical advances made by the company. They came to € 37.9m, co...

Bruno Cavalier
  • Bruno Cavalier

AI is everywhere, except in economic statistics!

The US economy paints a multi-faceted picture. The stockmarket is ecstatic, statisticians are recording GDP growth only slightly above potential and surveys describe a cautious business climate. This is not the first time we have seen such a disconnect between the stockmarket and the real economy. The explanation on this occasion may stem from an AI effect. AI is raising hopes of stronger productivity gains and sustainable growth. The markets, as is their function, are focusing o...

Andreas Riemann ... (+3)
  • Andreas Riemann
  • Jean Danjou
  • Usama Tariq

ODDO BHF Small & MIDCAP MORNING NEWS - 28/03/2024

Hormis les Etats-Unis, les marchés de la construction devraient continuer à reculer en 2024 (-2% en Europe) avant de rebondir à la faveur d’une baisse des taux. Dans ce contexte, la différenciation entre les groupes se fera essentiellement sur leur capacité de résistance (mix géographique et prix/ coûts), l’allocation du capital (et situations spéciales) et leur valorisation. Face à cet environnement, nous relevons nos recommandations sur KONE (la modernisation comme relais de la Chin...

Nicolas Thorez
  • Nicolas Thorez

Netgem : Improvement in 2023 results, close to expectations. The finan...

>Improvement in 2023 results, close to our initial estimates - Netgem reported good 2023 results this morning. On 2023 revenues down a slight 2% to € 35.6m and a gross margin up 10% to € 22.0m, both already published, EBITDA grew 14% to € 7.8m, in line with our expectations (vs ODDO BHF € 7.7m). This margin improvement (+3.2 points) reflects the combined effect of gross margin growth and very good opex optimisation (limited growth of 7% in the year). After factoring i...

Emmanuel Matot
  • Emmanuel Matot

Soitec : Another warning, RF-SOI destocking still underway

>No sales growth expected in the upcoming FY 2025 - Soitec confirmed yesterday evening that it will reach its guidance targets for FY 2024 (year to end-March) which it had revised downwards in early February. Sales should therefore fall by around 10% organically and the EBITDA margin by around 1 point to 34%. The bad news concerns the flat sales performance expected this coming FY 2025, implying a level that is well below expectations (ODDO BHF = +13% and FactSet...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

LNA Santé : RN FY 2023: les chiffres sont assez conformes – Focus sur ...

>ROC – RNpg : en ligne avec le consensus - Le CA 2023 ressort à 736,1 M€ (+1,1% vs. +5,8% pour le CA hors immobilier), l’EBITDA 2023 atteint 148,8 M€ (+4,2% - css : 142,7 M€), le ROC 65 M€ (+1%) et le RNpg 23,4 M€ (-9,3%). Le parc en activité (incluant les lits en restructuration) représente 9 390 lits à fin 2023 (vs 9 335 en 2022) sur 85 établissements dont 8 376 lits en « régime de croisière ».LNA Santé guide sur une croissance organique de 4,5% en 2024 (CA d’e...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

OSE Immunotherapeutics : FY 2023 results contained no surprises - deci...

>Financial visibility out to 2026 - OSE reported its FY 2023 results yesterday after market close The operating loss will be € 23.0m, compared with € 18.4m in 2022, impacted in particular by a fall in sales to € 2.2m in 2023 from €1 8.3m in 2022. R&D costs are down to €17.2m (vs € 26.9m in 2022), followed by G&A at € 6.0m (vs € 6.7m in 2022). On the balance sheet, cash and cash equivalents at end-December 2023 were € 18.7m (vs € 25.6m in 2022). Including the $ 4...

Geoffroy Michalet
  • Geoffroy Michalet

Cegedim : 2023 guidance met… but negative one-offs… and sluggish cash ...

>In line with the guidance, admittedly… but otherwise not great - Cegedim’s 2023 results came out in line. For the record, it had already released its revenue figures back in January (+11%).The aim was merely to achieve growth in recurring operating income. This it achieved, with reported recurring operating income increasing by +23% to € 31.7m and bringing the margin to 5.1% (+50bp), even though we had expected more.However, there are other factors that und...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir

Moderna : An increasingly structured vaccine franchise

>Acceleration of all programmes against latent viruses - Moderna's Vaccines Day highlighted a coherent and ambitious mRNA portfolio against infectious diseases (28 vaccine candidates in development). In addition to its COVID-19 vaccine, we are particularly impressed by the progress of its vaccine against congenital CytoMegaloVirus (phase III, fully recruited; n=7300), the probability of success of which is improving over time (justifying extensions of indications to a...

Jean-François Granjon
  • Jean-François Granjon

Quadient : Real growth drivers… for the next road map

>Targets broadly reached for the 2021-2023 road map - During the roadshow, the management (CEO, CFO, HIR) first of all gave a recap on the performances and the achievement of the targets in the 2021-2023 plan (phase II “Drive Sustainable Value”, which followed on from the “Transform” plan in 2019-2020) even though the mix is a little different from what was expected. We would point out the remarkable performances in the historical MRS business with a 2021-2023 CAGR of...

Christophe Chaput
  • Christophe Chaput

Knaus Tabbert AG : 2023 results and 2024 targets broadly in line with ...

>2023 results in line with forecasts: EBITDA of € 123.8m vs € 123m estimated - For 2023, Knaus Tabbert has published results that were broadly in line with estimates. The publication was characterised by: 1/ sales growth of 37.3% to € 1,441m (already published), EBITDA of € 123.8m (vs our forecast of € 123m) i.e. an increase of 76.4%. The EBITDA margin was therefore 8.6%, which is in line with the group’s forecasts (EBITDA margin of 8.5% and 9%). Over and above volume...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch